ABSTRACT
RATIONALE AND OBJECTIVES: Medulloblastoma (MB) and Ependymoma (EM) in children, share similarities in age group, tumor location, and clinical presentation. Distinguishing between them through clinical diagnosis is challenging. This study aims to explore the effectiveness of using radiomics and machine learning on multiparametric magnetic resonance imaging (MRI) to differentiate between MB and EM and validate its diagnostic ability with an external set. MATERIALS AND METHODS: Axial T2 weighted image (T2WI) and contrast-enhanced T1weighted image (CE-T1WI) MRI sequences of 135 patients from two centers were collected as train/test sets. Volume of interest (VOI) was manually delineated by an experienced neuroradiologist, supervised by a senior. Feature selection analysis and the least absolute shrinkage and selection operator (LASSO) algorithm identified valuable features, and Shapley additive explanations (SHAP) evaluated their significance. Five machine-learning classifiers-extreme gradient boosting (XGBoost), Bernoulli naive Bayes (Bernoulli NB), Logistic Regression (LR), support vector machine (SVM), linear support vector machine (Linear SVC) classifiers were built based on T2WI (T2 model), CE-T1WI (T1 model), and T1 + T2WI (T1 + T2 model). A human expert diagnosis was developed and corrected by senior radiologists. External validation was performed at Sun Yat-Sen University Cancer Center. RESULTS: 31 valuable features were extracted from T2WI and CE-T1WI. XGBoost demonstrated the highest performance with an area under the curve (AUC) of 0.92 on the test set and maintained an AUC of 0.80 during external validation. For the T1 model, XGBoost achieved the highest AUC of 0.85 on the test set and the highest accuracy of 0.71 on the external validation set. In the T2 model, XGBoost achieved the highest AUC of 0.86 on the test set and the highest accuracy of 0.82 on the external validation set. The human expert diagnosis had an AUC of 0.66 on the test set and 0.69 on the external validation set. The integrated T1 + T2 model achieved an AUC of 0.92 on the test set, 0.80 on the external validation set, achieved the best performance. Overall, XGBoost consistently outperformed in different classification models. CONCLUSION: The combination of radiomics and machine learning on multiparametric MRI effectively distinguishes between MB and EM in childhood, surpassing human expert diagnosis in training and testing sets.
ABSTRACT
BACKGROUND: To predict tuberculosis (TB) treatment outcomes at an early stage, prevent poor outcomes ofdrug-resistant tuberculosis(DR-TB) and interrupt transmission. METHODS: An internal cohort for model development consists of 204 bacteriologically-confirmed TB patients who completed anti-tuberculosis treatment, with one pretreatment and two follow-up CT images (612 scans). Three radiomics feature-based models (RM) with multiple classifiers of Bagging, Random forest and Gradient boosting and two deep-learning-based models (i.e., supervised deep-learning model, SDLM; weakly supervised deep-learning model, WSDLM) are developed independently. Prediction scores of RM and deep-learning models with respectively highest performance are fused to create new fusion models under different fusion strategies. An additional independent validation was conducted on the external cohort comprising 80 patients (160 scans). RESULTS: For RM scheme, 16 optimal radiomics features are finally selected using longitudinal scans. The AUCs of RM for Bagging, Random forest and Gradient boosting were 0.789, 0.773 and 0.764 in the internal cohort and 0.840, 0.834 and 0.816 in the external cohort, respectively. For deep learning-based scheme, AUCs of SDLM and WSDLM were 0.767 and 0.661 in the internal cohort, and 0.823 and 0.651 in the external. The fusion model yields AUCs from 0.767 to 0.802 in the internal cohort, and from 0.831 to 0.857 in the external cohort. CONCLUSIONS: Fusion of radiomics features and deep-learning model may have the potential to predict early failure outcome of DR-TB, which may be combined to help prevent poor TB treatment outcomes.
